AVROBIO Inc. (AVRO)
NASDAQ: AVRO
· Real-Time Price · USD
1.40
-0.02 (-1.41%)
At close: Jun 20, 2024, 8:00 PM
-1.41% (1D)
| Bid | n/a |
| Market Cap | 5.24M |
| Revenue (ttm) | 3.6M |
| Net Income (ttm) | 30.31M |
| EPS (ttm) | 8.28 |
| PE Ratio (ttm) | 0.16908212560386474 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 204,382 |
| Avg. Volume (20D) | 19,048 |
| Open | 1.43 |
| Previous Close | 1.42 |
| Day's Range | 1.38 - 1.44 |
| 52-Week Range | 1.38 - 19.80 |
| Beta | 1.22 |
About AVRO
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry di...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 21, 2018
Employees 13
Stock Exchange NASDAQ
Ticker Symbol AVRO
Website https://www.avrobio.com